Article | Published:

A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation

Nature Genetics volume 43, pages 639647 (2011) | Download Citation

Abstract

Autosomal dominant polycystic liver disease results from mutations in PRKCSH or SEC63. The respective gene products, glucosidase IIβ and SEC63p, function in protein translocation and quality control pathways in the endoplasmic reticulum. Here we show that glucosidase IIβ and Sec63p are required in mice for adequate expression of a functional complex of the polycystic kidney disease gene products, polycystin-1 and polycystin-2. We find that polycystin-1 is the rate-limiting component of this complex and that there is a dose-response relationship between cystic dilation and levels of functional polycystin-1 following mutation of Prkcsh or Sec63. Reduced expression of polycystin-1 also serves to sensitize the kidney to cyst formation resulting from mutations in Pkhd1, the recessive polycystic kidney disease gene. Finally, we show that proteasome inhibition increases steady-state levels of polycystin-1 in cells lacking glucosidase IIβ and that treatment with a proteasome inhibitor reduces cystic disease in orthologous gene models of human autosomal dominant polycystic liver disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 37, 164–171 (2003).

  2. 2.

    et al. Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. Am. J. Hum. Genet. 67, 1598–1604 (2000).

  3. 3.

    et al. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am. J. Hum. Genet. 72, 691–703 (2003).

  4. 4.

    et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat. Genet. 36, 575–577 (2004).

  5. 5.

    , , , & Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat. Genet. 33, 345–347 (2003).

  6. 6.

    & Binding of secretory precursor polypeptides to a translocon subcomplex is regulated by BiP. Cell 88, 85–96 (1997).

  7. 7.

    , , , & Sec63p and Kar2p are required for the translocation of SRP-dependent precursors into the yeast endoplasmic reticulum in vivo. EMBO J. 20, 262–271 (2001).

  8. 8.

    , , & Interaction of BiP with the J-domain of the Sec63p component of the endoplasmic reticulum protein translocation complex. J. Biol. Chem. 274, 20110–20115 (1999).

  9. 9.

    , & Endoplasmic reticulum glucosidase II is composed of a catalytic subunit, conserved from yeast to mammals, and a tightly bound noncatalytic HDEL-containing subunit. J. Biol. Chem. 271, 27509–27516 (1996).

  10. 10.

    , & Quaternary and domain structure of glycoprotein processing glucosidase II. Biochemistry 40, 10717–10722 (2001).

  11. 11.

    & Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 73, 1019–1049 (2004).

  12. 12.

    , , , & Glucosidase II β subunit modulates N-glycan trimming in fission yeasts and mammals. Mol. Biol. Cell 20, 3974–3984 (2009).

  13. 13.

    The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosme 16. Cell 77, 881–894 (1994).

  14. 14.

    The International Polycystic Kidney Disease Consortium. Polycystic kidney disease: The complete structure of the PKD1 gene and its protein. Cell 81, 289–298 (1995).

  15. 15.

    et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272, 1339–1342 (1996).

  16. 16.

    , , , & Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr. Biol. 12, R378–R380 (2002).

  17. 17.

    , & The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J. Am. Soc. Nephrol. 13, 2508–2516 (2002).

  18. 18.

    et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 33, 129–137 (2003).

  19. 19.

    et al. Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum. Mol. Genet. 12, 2703–2710 (2003).

  20. 20.

    et al. Biliary and pancreatic dysgenesis in mice harboring a mutation in Pkhd1. Am. J. Pathol. 172, 417–429 (2008).

  21. 21.

    , , , & Fibrocystin is associated with polycystin-2 and regulates intracellular calcium. J. Am. Soc. Nephrol. 15, 12A (2004).

  22. 22.

    et al. The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat. Genet. 38, 191–196 (2006).

  23. 23.

    , & Ciliary dysfunction in developmental abnormalities and diseases. Curr. Top. Dev. Biol. 85, 371–427 (2008).

  24. 24.

    et al. Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. Proc. Natl. Acad. Sci. USA 99, 16981–16986 (2002).

  25. 25.

    et al. Polyductin undergoes notch-like processing and regulated release from primary cilia. Hum. Mol. Genet. 16, 942–956 (2007).

  26. 26.

    & Polycystic kidney disease, cilia, and planar polarity. Methods Cell Biol. 94, 273–297 (2009).

  27. 27.

    , , & The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87, 979–987 (1996).

  28. 28.

    et al. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol. Cell 2, 247–251 (1998).

  29. 29.

    et al. Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93, 177–188 (1998).

  30. 30.

    , , , & A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat. Med. 13, 1490–1495 (2007).

  31. 31.

    et al. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology 138, 360–371 (2010).

  32. 32.

    et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int. 31, 92–98 (2011).

  33. 33.

    , & Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J. Am. Soc. Nephrol. 13, 1837–1846 (2002).

  34. 34.

    et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum. Mol. Genet. 17, 1505–1516 (2008).

  35. 35.

    et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc. Natl. Acad. Sci. USA 106, 21819–21824 (2009).

  36. 36.

    et al. Syntaxin 5 regulates the endoplasmic reticulum channel-release properties of polycystin-2. Proc. Natl. Acad. Sci. USA 105, 15920–15925 (2008).

  37. 37.

    et al. PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation. Hum. Mol. Genet. 19, 16–24 (2010).

  38. 38.

    et al. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408, 990–994 (2000).

  39. 39.

    et al. Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proc. Natl. Acad. Sci. USA 106, 11558–11563 (2009).

  40. 40.

    et al. A novel mouse model reveals that polycystin-1 deficiency in ependyma and choroid plexus results in dysfunctional cilia and hydrocephalus. PLoS ONE 4, e7137 (2009).

  41. 41.

    et al. Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease. Hum. Mol. Genet. 11, 1845–1854 (2002).

  42. 42.

    et al. Loss of oriented cell division does not initiate cyst formation. J. Am. Soc. Nephrol. 21, 295–302 (2010).

  43. 43.

    et al. Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. Hum. Mol. Genet. 16, 1940–1950 (2007).

  44. 44.

    & One step at a time: endoplasmic reticulum-associated degradation. Nat. Rev. Mol. Cell Biol. 9, 944–957 (2008).

  45. 45.

    et al. Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. Am. J. Hum. Genet. 68, 355–363 (2001).

  46. 46.

    et al. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1. Am. J. Pathol. 168, 205–220 (2006).

  47. 47.

    et al. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum. Mol. Genet. 13, 3069–3077 (2004).

  48. 48.

    et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 75, 848–855 (2009).

  49. 49.

    & A new method for generating point mutations in bacterial artificial chromosomes by homologous recombination in Escherichia coli. Nucleic Acids Res. 29, E14 (2001).

  50. 50.

    et al. Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat. Genet. 24, 75–78 (2000).

  51. 51.

    , & A Cre recombinase transgene with mosaic, widespread tamoxifen-inducible action. Genesis 32, 8–18 (2002).

  52. 52.

    et al. Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum. Mol. Genet. 17, 1578–1590 (2008).

  53. 53.

    et al. Identification and characterization of polycystin-2, the PKD2 gene product. J. Biol. Chem. 274, 28557–28565 (1999).

Download references

Acknowledgements

Carfilzomib was a kind gift from Proteolix, Inc. This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)/ US National Institutes of Health (NIH) (R01DK51041 and R01DK54053 to S.S. and F31DK083904 to S.V.F.) and a grant from the Mizutani Foundation for Glycoscience (S.S.). We are grateful for support from the Nephrology Training Grant (T32DK007276) to S.V.F. and the Joseph LeRoy and Ann C. Warner Fund (S.S.). The authors are members of the Yale PKD Center (P50DK57328). We are grateful for Core services from the Yale O'Brien Kidney Center (P30DK079310).

Author information

Author notes

    • Xin Tian
    •  & Anna-Rachel Gallagher

    These authors contributed equally to this work.

Affiliations

  1. Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Sorin V Fedeles
    • , Xin Tian
    • , Anna-Rachel Gallagher
    • , Michihiro Mitobe
    • , Saori Nishio
    • , Seung Hun Lee
    • , Yiqiang Cai
    • , Lin Geng
    •  & Stefan Somlo
  2. Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Sorin V Fedeles
    •  & Stefan Somlo
  3. Department of Molecular, Cellular and Developmental Biology, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Craig M Crews
  4. Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Craig M Crews
  5. Department of Chemistry, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Craig M Crews

Authors

  1. Search for Sorin V Fedeles in:

  2. Search for Xin Tian in:

  3. Search for Anna-Rachel Gallagher in:

  4. Search for Michihiro Mitobe in:

  5. Search for Saori Nishio in:

  6. Search for Seung Hun Lee in:

  7. Search for Yiqiang Cai in:

  8. Search for Lin Geng in:

  9. Search for Craig M Crews in:

  10. Search for Stefan Somlo in:

Contributions

S.V.F. co-designed the study, performed the experiments and co-wrote the manuscript. X.T. and M.M. generated the mouse models. A.-R.G. performed experiments, participated in the experimental design and assisted in manuscript preparation. S.N., S.H.L., Y.C. and L.G. carried out experiments. C.M.C. participated in the proteasome inhibitor studies. S.S. came up with the study design and co-wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Stefan Somlo.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Note and Supplementary Figures 1–9.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ng.860

Further reading